CURRICULUM VITAE
`
`Richard C. Brundage, Pharm.D., Ph.D., FISOP
`Professor, Department of Experimental and Clinical Pharmacology
`Distinguished University Teaching Professor
`University of Minnesota
`
`
`
`PERSONAL INFORMATION
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Business Address:
`
`
`
`
`
`Home Address:
`
`
`
`Birth Record:
`
`
`
`Citizenship:
`
`University of Minnesota
`College of Pharmacy
`717 Delaware Street S.E., room 464
`Minneapolis, MN 55414
`(612) 624-3115
`
`1464 N. Victoria Street
`Saint Paul, MN 55117
`(651) 489-6674
`
`6 December 1952
`Saint Paul, MN
`Ramsey County
`
`United States of America
`
`1989 - 1996
`
`
`1984 - 1985
`
`
`
`1983 - 1984
`
`
`
`1981 - 1983
`
`
`1974 - 1977
`
`
`1970 - 1974
`
`
`Ph.D., Pharmaceutics
`University of Minnesota Graduate School
`
`American Society of Hospital Pharmacists
`Fellow in Clinical Pharmacokinetics
`St. Paul Ramsey Medical Center, St. Paul, MN
`
`Post-Doctoral Fellow in Neuropharmacology
`and Pharmacokinetics
`St. Paul Ramsey Medical Center, St. Paul, MN
`
`Doctor of Pharmacy
`College of Pharmacy, University of Minnesota
`
`B.S. in Pharmacy (with distinction)
`College of Pharmacy, University of Minnesota
`
`B.A. in Psychology
`College of Liberal Arts, University of Minnesota
`
`EDUCATION AND TRAINING
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 1 of 40
`
`Biogen Exhibit 2043
`Coalition v. Biogen
`IPR2015-01993
`
`

`
`Richard C. Brundage, Pharm.D., Ph.D. page 2
`
`PROFESSIONAL EXPERIENCE
`
`2010 – present
`
`Graduate Faculty in Experimental and Clinical Pharmacology
`
`
`
`Jan 2010 – Mar 2011
`
`Interim Associate Dean of Graduate Studies, College of Pharmacy
`
`2008 – present
`
`
`
`Jan – May 2008
`
`2002 – 2008
`
`
`
`2002 – 2010
`
`2001 – 2012
`
`2000 – 2002
`
`1996 – 2002
`
`
`1985 – 1989
`
`
`
`
`
`1977 – 1981
`
`
`1979 – 1981
`
`
`1977 – 1993
`
`
`Professor
`Experimental and Clinical Pharmacology
`College of Pharmacy, University of Minnesota
`
`University of Minnesota Semester Leave; Visiting Scientist; Food and Drug
`Administration, Silver Spring, MD
`
`Associate Professor
`Experimental and Clinical Pharmacology
`College of Pharmacy, University of Minnesota
`
`Senior Member, Graduate Faculty in Social, Administrative and Clinical
`Pharmacy, Graduate School, University of Minnesota
`
`Director of Graduate Studies/Director, Graduate Track in Experimental and
`Clinical Pharmacology
`
`Associate Member, Graduate Faculty in Social, Administrative and Clinical
`Pharmacy, Graduate School, University of Minnesota
`
`Research Associate
`College of Pharmacy, University of Minnesota
`
`Assistant Professor of Pharmacy
`College of Pharmacy, Medical University of South Carolina
`
`and
`Director, Clinical Pharmacokinetics Service
`Medical University Medical Center, Charleston, SC
`
`Instructor, Educational Development Services
`College of Pharmacy, University of Minnesota
`
`Registered Pharmacist, Dvorak Drug
`Minneapolis, MN
`
`Registered Pharmacist, Desnick Drug
`Saint Paul, MN
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 2 of 40
`
`

`
`Richard C. Brundage, Pharm.D., Ph.D. page 3
`
`HONORS AND AWARDS
`
`
`2016
`2014
`2012
`
`2008
`
`2008
`1999
`
`1986
`1984
`1983
`1977
`1977
`1977
`1976
`1976
`
`Bristol-Myers Squibb Mentorship Award; American College of Clinical Pharmacology
`Fellow, International Society of Pharmacometrics; Inaugural cohort
`Outstanding Adviser Award; University of Minnesota Graduate and Professional
`Student Association (GAPSA)
`Distinguished University Teaching Professor; Award for Outstanding Contributions to
`Graduate and Professional Education; University of Minnesota Alumni Association
`Excellence in Graduate Education; College of Pharmacy
`AAPS Meritorious Manuscript Award
`Yang Z, Brundage RC, Barbhaiya RH, and Sawchuk RJ; “Microdialysis Studies
`of the Distribution of Stavudine into the Central Nervous System in the Freely-
`Moving Rat”; Pharm Res 1997; 14(7):865-72.
`Certificate of Merit, Epilepsy Association of South Carolina
`ASHP Fellowship in Clinical Pharmacokinetics
`Roche Pharmacy Communications Award
`Graduation with Distinction
`Harold R. Popp Award
`Eleventh Annual SAPhA Paper Review Forum, 2nd place
`John Y. Breckenridge Memorial Award
`Kappa Psi Scholarship Award
`
`
`
`PROFESSIONAL MEMBERSHIPS
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`International Society of Pharmacometrics
`American College of Clinical Pharmacology
`American Society of Clinical Pharmacology and Therapeutics
`American Association of Pharmaceutical Scientists
`
`
`
`
`
`
`
`
`
`
`
`Academy of Distinguished Teachers, University of Minnesota
`Rho Chi Professional Pharmacy Honor Society
`Kappa Psi Pharmaceutical Fraternity
`Century Mortar Club, University of Minnesota Foundation
`Who's Who in American Colleges and Universities
`
`HONORARY/FRATERNAL MEMBERSHIPS
`
`
`
`
`
`
`
`
`
`
`PHARMACY LICENSURE
`
`
`1977 – 2014
`
`Minnesota
`
`
`
`Page 3 of 40
`
`

`
`Richard C. Brundage, Pharm.D., Ph.D. page 4
`
` PUBLICATIONS, Refereed Journals
`
`Garnett C, Needleman K, Liu J, Brundage R, Wang Y. Operational Characteristics of Linear Concentration-
`QT Models for Assessing QTc Interval in the Thorough QT and Phase 1 Clinical Studies. Clin Pharmacol
`Ther. 2016 Mar 4. doi: 10.1002/cpt.361. [Epub ahead of print]. PMID:26946218.
`
`Sanghavi K, Wiseman A, Kirstein MN, Cao Q, Brundage R, Jensen K, Rogosheske J, Kurtzweil A, Long-
`Boyle J, Wagner J, Warlick ED, Brunstein CG, Weisdorf DJ, Jacobson PA. Personalized fludarabine
`dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced
`intensity conditioning. Transl Res. 2016 Mar 31. pii: S1931-5244(16)30001-9. doi:
`10.1016/j.trsl.2016.03.017. [Epub ahead of print]. PMID: 27094990.
`Liang S, Brundage RC, Jacobson PA, Blaes A, Kirstein MN. Pharmacokinetic-pharmacodynamic modeling of
`acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer. Br J Clin
`Pharmacol. 2016; Apr 29. doi: 10.1111/bcp.12989. [Epub ahead of print]; PMID: 27128712.
`
`Sanghavi K, Brundage RC, Miller MB, Schladt DP, Israni AK, Guan W, Oetting WS, Mannon RB, Remmel
`RP, Matas AJ, Jacobson PA. Genotype-guided tacrolimus dosing in African-American kidney transplant
`recipients. Pharmacogenomics J. 2015; Dec 15. doi: 10.1038/tpj.2015.87. [Epub ahead of print]; PMID:
`26667830.
`
`Ahmed MA, Kartha RV, Brundage RC, Cloyd J, Basu C, Carlin BP, Jones RO, Moser AB, Fatemi A,
`Raymond GV. A model-based approach to assess the exposure-response relationship of Lorenzo's oil in
`adrenoleukodystrophy. Br J Clin Pharmacol. 2016; Jun;81(6):1058-66. PMID: 26836218.
`Lim CN, Birnbaum AK, Brundage RC, Leppik IE, Cloyd JC, Clark A, Marino SE. Pharmacokinetic-
`pharmacodynamic modeling of intravenous and oral topiramate and its effect on the symbol digit
`modalities test in adult healthy volunteers. J Clin Pharmacol. 2016; Jun;56(6):714-22. PMID: 26395889.
`
`Polepally AR, Remmel RP, Brundage RC, Leppik IE, Rarick JO, Ramsay RE, Birnbaum AK. Steady-state
`pharmacokinetics and bioavailability of immediate-release and extended-release formulations of
`lamotrigine in elderly epilepsy patients: Use of stable isotope methodology. J Clin Pharmacol. 2015;
`55(10):1101-8. PMID: 25903807.
`
`Sarafoglou K, Zimmerman CL, Gonzalez-Bolanos MT, Willis B, Brundage RC. Interrelationships among
`cortisol, 17-hydroxyprogesterone, and androstenedione exposures in the management of children with
`congenital adrenal hyperplasia. J Investig Med 2015; 63(1):35-41. PMID: 25386671.
`
`Sarafoglou K, Gonzalez-Bolanos MT, Zimmerman CL, Boonstra T, Yaw AO, Brundage RC. Comparison of
`cortisol exposures and pharmacodynamic adrenal steroid responses to hydrocortisone suspension vs.
`commercial tablets. J Clin Pharmacol 2015; 55(4):452-7. PMID: 25385533.
`
`Ahmed GF, Marino SE, Brundage RC, Pakhomov SV, Leppik IE, Cloyd JC, Clark A, Birnbaum AK.
`Pharmacokinetic-pharmacodynamic modeling of intravenous and oral topiramate and its effect on
`phonemic fluency in adult healthy volunteers. Br J Clin Pharmacol 2015; 79(5):820-30. PMID: 25403343.
`
`Bart G, Lenz S, Straka RJ, Brundage RC. Ethnic and genetic factors in methadone pharmacokinetics: A
`population pharmacokinetic study. Drug Alcohol Depend 2014; 145:185-93. PMID: 25456325.
`
`Vezina HE, Brundage RC, Balfour HH. Population Pharmacokinetics of valganciclovir prophylaxis in
`paediatric and adult solid organ transplant recipients. Br J Clin Pharmacol 2014; 78(2):343-52. PMID:
`24528138.
`
`Polepally AR, Pennell PB, Brundage RC, Stowe ZN, Newport DJ, Viguera AC, Ritchie JC, Birnbaum AK.
`Model-based lamotrigine clearance changes during pregnancy: Clinical implication. Ann Clin Transl
`Neurol. 2014;1(2):99-106. PMID: 24883336.
`
`Page 4 of 40
`
`

`
`Richard C. Brundage, Pharm.D., Ph.D. page 5
`
`Salem AH, Fletcher CV, Brundage RC. Pharmacometric characterization of efavirenz developmental
`pharmacokinetics and pharmacogenetics in HIV-infect children. Antimicrob Agents Chemother 2014;
`58(1):136-43. PMID:24145522.
`
`Wang T, Baron K, Zhong W, Brundage R, Elmquist W. Bayesian approach to estimate AUC, partition
`coefficient and drug targeting index for studies with serial sacrifice design. Pharm Res 2014; 31:649-659.
`PMID:240920512.
`Khatri A, Williams BW, Fisher J, Brundage RC, Gurvich VJ, Lis LG, Skubitz KM, Dudek AZ, Greeno EW,
`Kratzke RA, Lamba JK, Kirstein MN. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP
`metabolite disposition in patients with solid tumours. Br J Cancer 2014; 110(2):304-12. PMID:24300978.
`
`Clark AM, Kriel RL, Leppik IE, White JR, Henry TR, Brundage RC, Cloyd JC. Intravenous topiramate: Safety
`and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral
`topiramate. Epilepsia 2013; 54(6):1106-11. PMID:23586686.
`
`Clark AM, Kriel RL, Leppik IE, Marino SE, Mishra U, Brundage RC, Cloyd JC. Intravenous topiramate:
`Comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. Epilepsia;
`2013; 54(6):1099-105. PMID:23506041.
`
`Agarwal SK, Kriel RL, Brundage RC, Ivaturi VD, Cloyd JC. A pilot study assessing the bioavailability and
`pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers.
`Epilepsy Res 2013; 105(3):362-7. PMID:23561287.
`
`Ahmed GF, Brundage RC, Marino SE, Cloyd JC, Leppik IE, Pennell PB, Ramsay RE, Birnbaum AK.
`Population pharmacokinetics of unbound and total drug concentrations following intravenously
`administered carbamazepine in elderly and younger adult patients with epilepsy. J Clin Pharmacol 2013;
`53(3):276-84. PMID:23408495.
`
`Munn MS, Sibley S, Brundage RC, Ismail B, Earthman CP. Angiotensin-converting enzyme inhibitory effects
`of dairy- and soy-derived peptides in pre-hypertensive overweight men and wormen. Functional Foods in
`Health and Disease 2013; 3(1):37-47.
`
`
`Milan Segovia RC, Dominguez Ramirez AM, Jung Cook H, Magana Aquino M, Vigna Perez M, Brundage
`RC, Romano Moreno S. Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis.
`J Clin Pharmacol Therap 2013; 38:56-61. PMID:23167603.
`
`
`Ivaturi V, Kriel R, Brundage RC, Loewen G, Mansbach H, Cloyd JC. Bioavailability of intranasal vs. rectal
`diazepam. Epilepsy Res 2013 Feb; 103(2-3):254-61. PMID:22981338.
`
`
`Holman CJ, Karger AB, Mullan BD, Brundage RC, Balfour HH Jr Quantitative Epstein-Barr virus shedding
`and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant 2012;
`26:741-7. PMID:22385033.
`
`
`Punyawudho B, Ramsay ER, Brundage RC, Macias FM, Collins JF, Birnbaum AK. Population
`pharmacokinetics of carbamazepine in elderly patients. Ther Drug Monit 2012; 34(2):176-81.
`PMID:22406657.
`
`
`Marino SE, Birnbaum AK, Leppik IE, Conway JM, Musib LC, Brundage RC, Ramsay RE, Pennell PB, White
`JR, Gross CR, Rarick JO, Mishra U, Cloyd JC. Steady-state carbamazepine pharmacokinetics following
`oral and stable-labeled intravenous administration in epilepsy patients: Effects of race and sex. Clin
`Pharmacol Therap 2012; 91(3):483-8. PMID:22278332.
`
`
`Passey C, Birnbaum AK, Brundage RC, Schladt DP, Oetting WS, Leduc RE, Israni AK, Guan W, Matas AJ,
`Jacobson PA. Validation of tacrolimus equation to predict troughs using genetic and clinical factors.
`Pharmacogenomics 2012; 13(10):1141-7. PMID:22909204.
`
`
`
`Page 5 of 40
`
`

`
`Richard C. Brundage, Pharm.D., Ph.D. page 6
`
`D'Argenio DZ, Gastonguay MR, Brundage RC, Miller R, Tannenbaum SJ, Pfister M. Affiliation between the
`American Society of Pharmacometrics and the Journal of Pharmacokinetics and Pharmacodynamics. J
`Pharmcokinet Pharmacodyn 2012; 39(1):3.
`
`
`Kim H, Long-Boyle J, Rydholm N, Orchard PJ, Tolar J, Smith AR, Jacobson P, Brundage R. Population
`pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing
`allogeneic hematopoietic cell transplantation. J Clin Pharmacol 2012; 52:1665-75.
`
`
`Khatri A, Brundage RC, Hull JM, Williams BW, Yee D, Kirstein MN. Pharmacodynamic Modeling of
`Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine. AAPS J
`2012; 14(1):1-9.
`
`
`Khatri A, Gaber M, Brundage RC, Naimark M, Hanna S, Stewart C, Kirstein, MN. Effect of radiation on the
`penetration of irinotecan in rat cerebrospinal fluid. Cancer Chemotherap Pharmacol 2011; 68(3):721-31.
`
`
`Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus
`using genetic variants and clinical factors. Br J Clin Pharmacol 2011; 72(6):948-57.
`
`
`Kiser JJ, Rutstein RM, Samson P, Graham B, Aldrovandi G, Mofenson LM, Smith E, Schnittman S, Fenton T,
`Brundage RC, Fletcher CV. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants,
`children, and adolescents. AIDS 2011; 25:1489-96.
`
`
`Florian JA, Tornoe CW, Brundage RC, Parekh A, Garnett CE. Population pharmacokinetic and
`concentration-QTc models for moxifloxacin : Pooled analysis of 20 thorough QT studies. J Clin
`Pharmacol 2011; 51:1152-1162.
`
`
`Kolesar JM, Brundage RC, Pomplun M, Alberti D, Holen J, Traynor A, Ivy P, Wilding, G. Population
`pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer
`patients. Cancer Chemotherap Pharmacol 2011; 67(2):393-400.
`
`
`Aliwarga T, Cloyd JC, Goel V, Brundage RC, Marino SE, Leppik IE, Remmel RP. Excretion of the principal
`urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in
`patients with epilepsy. Ther Drug Monit 2011; 33(1):56-63.
`
`
`Kiser JJ, Bumpass JB, Meditz AL, Anderson PL, Bushman L, Ray M, Predhomme JA, Rower J, MaWhinney
`S, Brundage RC. Effect of Antacids on the Pharmacokinetics of Raltegravir in Human Immunodeficiency
`Virus Seronegative Volunteers. Antimicrobial Agents and Chemotherapy 2010; 54(12):499-5003.
`
`
`Brundage RC, Pfister M, D’Argenio DZ, Gastonguay MR, Miller R, Tannenbaum SJ. ACoP: The tools,
`carpenters, and architects building the discipline of pharmacometrics. J Clin Pharmacol 2010; 50:7S-8S.
`
`
`Pfister M, Brundage RC, Gastonguay MR, Miller R, Tannenbaum SJ, D’Argenio DZ. Defining the future of
`pharmacometrics: the American Society of Pharmacometrics. J Clin Pharmacol 2010; 50:158S.
`
`
`Vezina HE, Balfour HH, Weller DR, Anderson BJ, Brundage RC. Valacyclovir pharmacokinetics and
`exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis. J Clin
`Pharmacol 2010; 50:734-72.
`
`
`Vezina HE, Brundage RC, Nevins TE, Balfour HH. The pharmacokinetics of valganciclovir prophylaxis in
`pediatric solid organ transplant patients at risk for Epstein-Barr virus disease. Clinical Pharmacology:
`Advances and Applications. 2010; 2:1-7.
`
`
`Castro N, Marquez-Caraveo M, Brundage RC, Gonzalez-Esquivel D, Suarez AM, Gongora F, Jara A, Urizar
`J, Lanao JM, Jung H. Population pharmacokinetics of albendazole in patients with neurocysticercosis. Int
`J Clin Pharmacol Ther 2009; 47(11):679-85.
`
`
`Paulo RC, Brundage RC, Cosma M, Mielke KL, Bowers CY, Veldhuis JD. Estrogen elevates the peak
`overnight production rate of acetylated Ghrelin. J Clin Endocrinol Metab 2008; 93(11):4440-7.
`
`
`
`Page 6 of 40
`
`

`
`Richard C. Brundage, Pharm.D., Ph.D. page 7
`
`Johnson L, Orchard PJ, Baker KS, Brundage RC, Cao Q, Xinjing W, Langer E, Farag-El Maasah S, Ross
`JA, Remmel RP, Jacobson PA. Glutathione-s-transferase A1 genetic variants reduce busulfan clearance
`in children undergoing hematopoietic cell transplantation. J Clin Pharmacol 2008; 48:1052-62.
`
`
`Ahn JE, Cloyd JC, Brundage RC, Marino SE, Conway JM, Ramsay RE, White JR, Musib LC, Rarick JO,
`Birnbaum AK, Leppik IE. Phenytoin half-life and clearance during maintenance therapy in adults and
`elderly with epilepsy. Neurology 2008; 71(1):38-43.
`
`
`Kumar V, Brundage RC, Oetting WS, Leppik IE, Tracy TS. Differential genotype dependent inhibition of
`CYP2C9 in humans. Drug Metab Dispos 2008; 36(7):1242-8.
`
`
`Byon WK, Fletcher CV, Brundage RC. Impact of censoring data below an arbitrary quantification limit on
`structural model misspecification. J Pharmacokinet Pharmacodynam 2008; 35:101-16; PMID:17963024.
`
`
`Punyawudho B, Ramsay RE, Macias FM, Rowan AJ, Collins JF, Brundage RC, Birnbaum AK. Population
`pharmacokinetics of lamotrigine in elderly patients. J Clin Pharmacol 2008; 48:455-63.
`
`
`Fletcher CV, Brundage RC, Fenton T, Alvero CG, Powell C, Mofenson LM, Spector SA. Pharmacokinetics
`and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an Area-
`Under-the-Curve controlled trial. Clin Pharmacol Therap 2008; 83(2):300-6.
`
`
`Kirstein MN, Brundage RC, Moore MM, Williams BW, Hillman LA, Dagit JW, Fisher JE, Marker PH, Kratzke
`RA, Yee D. Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture
`bioreactor system. Cancer Chemotherap Pharmacol 2008; 61(2):291-9.
`
`
`Huang J, Jacobson PA, Brundage RC. Prediction of unbound mycophenolic acid concentrations in patients
`after hematopoietic cell transplant. Therapeutic Drug Monitoring 2007; 29(4):385-90.
`
`
`Birnbaum AK, Ahn JE, Brundage RC, Hardie NA, Conway JM, Bowers SE, Leppik IE. Population
`pharmacokinetics of valproic acid concentrations in elderly nursing home residents. Therapeutic Drug
`Monitoring 2007; 29(5):571-5.
`
`
`Acosta EP, Brundage RC, King JR, Sanchez PJ, Agraway V, Homans J, Jacobs RF, Lang D, Romero JR,
`Griffin J, Cloud G, Whitley R, Kimberlin DW. Ganciclovir population pharmacokinetics in neonates
`following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir
`formulation. Clin Pharmacol Therap 2007; 81(6):867-72.
`
`
`Balfour HH, Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Holman CJ, Vezina HE, Brundage
`RC. A virologic pilot study of valacyclovir for infectious mononucleosis. J Clin Virology 2007; 39:16-21.
`
`
`Saitoh A, Fletcher CV, Brundage RC, Alvero C, Fenton T, Hsia K, Spector SA. Efavirenz pharmacokinetics in
`HIV-1 infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr
`2007; 45(3):280-5.
`
`
`Weller DR, Brundage RC, Balfour HH, Vezina HE. An isocratic liquid chromatography method for
`determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in
`human plasma. J Chromatogr B 2007; 848(2):369-373.
`
`
`Kaila N, Straka RJ, Brundage RC. Mixture models and subpopulation classification: A pharmacokinetic
`simulation study and application to metoprolol CYP2D6 phenotype. J Pharmacokinet Pharmacodynam
`2007; 34(2):141-56; PMID:17053980.
`
`
`Kirstein MN, Brundage RC, Elmquist WF, Remmel RP, Marker PH, Guire DE, and Yee D. Characterization of
`an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Res
`Treat 2006; 96(3):217-225.
`
`
`Vezina HE, Henry K, Ravindran GD, Kurpad AV, Raj TDS, Fox K, Weller D, Brundage RC, Cavert W, Balfour
`HH. A randomized crossover study to determine bioequivalence of generic and brand name nevirapine,
`
`Page 7 of 40
`
`

`
`Richard C. Brundage, Pharm.D., Ph.D. page 8
`
`zidovudine & lamivudine in HIV-negative women in India. J Acquir Immune Defic Syndr 2006; 41(2):131-
`6.
`
`
`Dickson RC, Terrault NA, Ishitani M, Reddy KR, Sheiner P, Luketic V, Soldevila-Pico C, Fried M, Jensen D,
`Brown Jr RS, Horwith G, Brundage RC, Lok A. Protective antibody levels and dose requirements for IV
`5% Nabi Hepatitis B Immune Globulin combined with lamivudine in liver transplantation for hepatitis B-
`induced end-stage liver disease. Liver Transpl 2006; 12:124-33.
`
`
`Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta RP, Martinez A, Jiang H, Gulick
`RM. Four measures of antiretroviral medication adherence and virologic response in AIDS Clinical Trials
`Group Study 359. J Acquir Immune Defic Syndr 2005; 40(3):301-6.
`
`
`Balfour HH, Holman CJ, Hokanson KM, Lelonek MM, Giesbrecht JE, White DR, Schmeling DO, Webb C,
`Cavert W, Wang DH, Brundage RC. A prospective clinical study of Epstein-Barr Virus and host
`interactions during acute infectious mononucleosis. J Infect Dis 2005;192:1505-12.
`
`
`Ahn JE, Birnbaum AK, Brundage RC. Inherent correlation between dose and clearance in therapeutic drug
`monitoring settings: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet
`Pharmacodyn 2005; 32(5,6):703-18; PMID:16328100.
`
`
`Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage RC, Starr SA, Spector SA. A
`polymorphism in MDR1-3435 is associated with higher plasma nelfinavir levels and more rapid virologic
`response in HIV-1 infected children. AIDS 2005; 19(4):371-80.
`
`
`King JR, Wynn HE, Brundage RC, Acosta EP. Pharmacokinetic enhancement of protease inhibitor therapy.
`Clin Pharmacokinet 2004; 43(5):291-310.
`
`
`Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM. Sex differences in
`saquinavir pharmacology and virologic response in AIDS Clinical Trials Group study 359. J Infect Dis
`2004; 189:1176-84.
`
`
`Brundage RC, Yong FH, Fenton T, Spector SA, Starr SE, Fletcher CV. Intrapatient variability of efavirenz
`concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrobial Agents and
`Chemotherapy 2004; 48:979-84; PMID:14982792.
`
`
`
`Belldina EB, Huang MY, Schneider JA, Brundage RC, Tracy TS. Steady-state pharmacokinetics and
`pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. Br J Clin
`Pharmacol 2003; 56:520-25.
`
`
`Jacobson PA, Ng J, Green KGE, Rogosheske J, Brundage RC. Posttransplant day significantly influences
`pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation. Biol Blood Marrow
`Transplantation 2003; 9:304-11.
`
`
`Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS
`Drugs 2002; 16(9):595-609.
`
`
`Starr SE, Fletcher CV, Spector SA, Brundage RC, Yong FH, Douglas SD, Flynn PM, Kline MW. Efavirenz
`liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002;
`21(7):659-63.
`
`
`Anderson PL, Brundage RC, Kakuda TN, Fletcher CV. CD4 response is correlated with peak plasma
`concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid.
`Clin Pharmacol Therap 2002; 71:280-5.
`
`
`Grub S, DeLora P, Ludin E, Duff, F, Fletcher CV, Brundage RC, Kline MW, Callas NR, Schwarzwald N,
`Jorga K. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human
`immunodeficiency syndrome. Clin Pharmacol Therap 2002; 71:122-30.
`
`
`
`Page 8 of 40
`
`

`
`Richard C. Brundage, Pharm.D., Ph.D. page 9
`
`Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, and Brundage RC.
`Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002;
`16:551-60.
`
`
`Jacobson PA, Ng J, Ratanatharathorn V, Uberti J, Brundage RC. Factors affecting pharmacokinetics of
`tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplantation 2001;
`28:753-8.
`
`
`Kline MW, Brundage RC, Fletcher CV, Schwartzwald H, Calles NR, Buss NE, Snell P, DeLora P, Eason M,
`Jorga K, Craig C, Duff F. Combination therapy with saquinavir soft gelatin capsules in children with
`human immunodeficiency virus infection. Pediatr Infect Dis J 2001; 20(7):666-71.
`
`
`Kakuda TN, Page LM, Anderson PL, Henry K, Schacker T, Rhame F, Acosta EP, Brundage RC, and
`Fletcher CV. Pharmacologic basis for concentration-controlled therapy with zidovudine, lamivudine, and
`indinavir. Antimicrobial Agents and Chemotherapy 2001; 45:236-42.
`
`
`Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, Brundage RC, Remmel RP.
`Zidovudine- and lamivudine-triphosphate concentration-response relationships in HIV-infected persons.
`AIDS 2000; 14:2137-44.
`
`
`Anderson PL, Brundage RC, Bushman LR, Remmel RP, Kakuda TN, and Fletcher CV. Indinavir plasma
`protein binding in HIV 1-infected adults. AIDS 2000; 14:2293-97.
`
`
`Anderson PL, Noormohamed SE, Henry K, Brundage RC, Balfour HH Jr., and Fletcher CV. Semen and
`serum pharmacokinetics of zidovudine and zidovudine-glucuronide in HIV-1 infected men.
`Pharmacotherapy 2000; 20(8):917-22.
`
`
`Acosta EP, Brundage RC, Kakuda TN, Anderson PL, Fletcher CV. Pharmacodynamics of HIV-1 protease
`inhibitors. Clinical Infectious Diseases 2000; 30(suppl 2):S151-9.
`
`
`Chen SA, Sawchuk RJ, Brundage RC, Horvath C, Mendenhall HV, Gunther RA, and Braeckman RA.
`Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-
`modified interleukin-2 in pigs. J Pharmacol Exp Ther 2000; 293:248-59.
`
`
`Fletcher CV, Brundage RC, Remmel RP, Page LM, Weller D, Calles NR, Simon C, Kline MW.
`Pharmacologic characteristics of indinavir, didanosine and stavudine in HIV-infected children receiving
`combination therapy. Antimicrobial Agents and Chemotherapy 2000; 44:1029-34.
`
`
`Starr SE, Fletcher CV, Spector SA, Yong F, Fenton T, Brundage RC, Lischner H, Dankner WM, Flynn PM,
`Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, for the PACTG 382 Team.
`Combination therapy with efavirenz and nelfinavir, and nucleoside reverse transcriptase inhibitors in
`children infected with human immunodeficiency virus type 1. New England Journal of Medicine 1999;
`25:1874-81.
`
`
`Kline MW, Blanchard S, Fletcher CV, Shenep JL, McKinney RE, Brundage RC, Culnane M, Van Dyke RB,
`Dankner WM, Kovacs A, McDowell JA and Hetherington S, for the AIDS Clinical Trials Group 330 Team.
`A phase I study of abacavir alone and in combination with other antiretroviral agents in infants and
`children with human immunodeficiency virus infection. Pediatrics 1999; 103(4),e47:1-5.
`
`
`Kline MW, Fletcher CV, Harris AT, Evans KD, Brundage RC, Remmel RP, Calles NR, Kirkpatrick SB, and
`Simon C. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in
`children infected with the human immunodeficiency virus. J Pediatr 1998; 132(3):543-6.
`
`
`Graves NM, Brundage RC, Wen Y, Cascino G, Elson S, Ahman P, Rarick J, Krause S, Leppik IE.
`Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy 1998;
`18(2):273-81.
`
`
`Yang Z, Brundage RC, Barbhaiya RH, and Sawchuk RJ. Microdialysis studies of the distribution of
`stavudine into the central nervous system in the freely-moving rat. Pharm Res 1997; 14(7):865-72.
`
`Page 9 of 40
`
`

`
`Richard C. Brundage, Pharm.D., Ph.D. page 10
`
`
`Malhotra BK, Brundage RC, Lemaire M, and Sawchuk RJ. Modeling the route of administration-based
`enhancement in the brain delivery of EAB 515, studied by microdialysis. Journal of Drug Targetting
`1997; 4(5):277-88.
`
`
`Shah AK, Brundage RC, Lake KD, and Sawchuk RJ. The estimation of the plasma free fraction of
`cyclosporine in rabbits and heart transplant patients: application of a physiological model of renal
`clearance. Biopharm Drug Dispos 1995;16:59-70.
`
`
`Seay RE, Brundage RC, Jensen PD, Schilling CG, and Edgren BE. Population pharmacokinetics of
`vancomycin in neonates. Clin Pharm Ther 1994;56:169-75.
`
`
`Shah AK, Brundage RC, Gratwohl A, and Sawchuk RJ. Pharmacokinetic model for subcutaneous
`absorption of cyclosporine during chronic dosing in the rabbit. J Pharm Sci 1992; 81(6):491-5.
`
`
`Jensen PD, Edgren B, Brundage RC, Coleman M, Mammel M, and Boros S. Population pharmacokinetics of
`gentamicin in neonates using a nonlinear mixed effects model. Pharmacotherapy 1992; 12(1):178-82.
`
`
`Weist DB, Pinson JB, Gal PS, Brundage RC, Schall S, Ransom JL, Weaver RL, Purohit D, and Brown Y.
`Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus
`arteriosus. Clin Pharm Ther 1991; 49(5):550-7.
`
`
`Uber W, Brundage RC, White RL, and Brundage DM. In vivo inactivation of tobramycin by piperacillin. Drug
`Intell Clin Phar 1991; 25(4):357-9.
`
`
`Graves NM, Fuerst RH, Cloyd JC, Brundage RC, Welty TE, and Leppik IE. Progabide induced changes in
`carbamazepine metabolism. Epilepsia 1989; 29(6):775-780.
`
`
`Weist DB, O’Neal W, Reigart JR, Brundage RC, Gillette PC, and Yost RL. Pharmacokinetics of ranitidine in
`critically ill infants. Developmental Pharmacology and Therapeutics 1989; 12(1):7-12.
`
`
`Fuerst RH, Graves NM, Leppik IE, Brundage RC, Holmes GB, and Remmel RP. Felbamate increases
`phenytoin but decreases carbamazepine concentrations. Epilepsia 1988; 29(4):488-491.
`
`
`Brundage RC, Cloyd JC, Leppik IE, Graves NM, and Welty TE, The effect of progabide on serum phenytoin
`and carbamazepine concentrations. Clin Neuropharmacol 1987; 10(6):545-554.
`
`
`Leppik IE, Dreifuss FE, Bowman TE, et al. A double-blind crossover evaluation of progabide in partial
`seizures. Neurology 1987; 37(6):963-968.
`
`
`Leppik IE, Brundage RC, Krall RL, Cloyd TB, Jacobs MP, and Cloyd JC. Double blind withdrawal of
`phenytoin and carbamazepine in patients treated with progabide. Epilepsia 1986; 27(5):563-568.
`
`
`Matzke GR, Brundage RC, Sawchuk RJ. Protein Binding of phenytoin, p-hydroxy phenytoin and p-hydroxy
`phenytoin glucuronide. J Clin Pharmacol 1986; 26:577-579.
`
`
`Cloyd JC, and Brundage RC. Monitoring antiepileptic drugs. Clin Pharmacol 1985; 6(1):1-5.
`
`
`
`Page 10 of 40
`
`

`
`Richard C. Brundage, Pharm.D., Ph.D. page 11
`
`PUBLICATIONS, Chapters In Texts
`
`Brundage RC and Mann HJ. General Principles of Pharmacokinetics and Pharmacodynamics. In Textbook
`of Critical Care, Sixth Edition, Vincent JL, Abraham E, Moore FA, Kochanek P, Fink MP (eds) Elsevier
`Inc, Philadelphia, PA, 2011.
`
`
`Brundage RC and Mann HJ. General Principles of Pharmacokinetics and Pharmacodynamics. In Textbook
`of Critical Care, Fifth Edition, Fink MP, Abraham E, Vincent JL, and Kochanek P, (eds) Elsevier Inc,
`Philadelphia, PA, 2005.
`
`
`Cloyd JC, and Brundage RC. Valproic Acid. In Therapeutic Drug Monitoring as a Basis for Individualizing
`Drug Therapy, Taylor WJ, (ed.), Abbott Diagnostics, Irvine, TX, 1986.
`
`
`Cloyd JC, Brundage RC, Leppik IE, Graves NM, and Welty TE. Effect of progabide on serum phenytoin and
`carbamazepine concentrations: a preliminary report. In Epilepsy and GABA Receptor Agonists: Basic
`and Therapeutic Research, Bartholini G, Bossi L, Lloyd KG, and Morselli PL, (eds.) Raven Press, New
`York, 1985.
`
`
`Brundage RC. Managing medications in the home and minimizing drug use problems. In Caresharing: How
`to Relate to the Frail Elderly, Gray VK, (ed.), Ebenezer Center for Aging and Human Development,
`Minneapolis, MN, 1984.
`
`
`
`PUBLICATIONS, Letters (* indicates refereed work)
`
`*Henry K, Brundage RC, Weller D, Akinsete O, Shet A. Comparison of generic zidovudine plus lamivudine
`(Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tablets. J Acquir Immune Defic Syndr [letter]
`2004; 35(5